SPECTRUM PHARMACEUTICALS (NASDAQ: SPPI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Class Action by September 24, 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 08 2025
0mins
Should l Buy ASRT?
Source: PRnewswire
Securities Fraud Investigation: Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. for investors who acquired shares between March 17, 2022, and September 22, 2022, alleging false statements regarding the Pinnacle Study related to the drug poziotinib.
Class Action Details: Investors have until September 24, 2025, to seek appointment as lead plaintiff in the class action lawsuit, following Spectrum's shares being delisted after its merger with Assertio Holdings, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASRT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASRT
Wall Street analysts forecast ASRT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 12.210
Low
35.00
Averages
40.00
High
45.00
Current: 12.210
Low
35.00
Averages
40.00
High
45.00
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Assertio Holdings Regains Nasdaq Compliance with Minimum Bid Price Rule
- Compliance Regained: Assertio Holdings announced that as of January 12, 2026, it has successfully regained compliance with Nasdaq listing requirements by maintaining a minimum bid price of $1.00 per share for ten consecutive days, marking a significant achievement in capital allocation flexibility.
- Successful Reverse Split: The company effectively increased its stock price through a reverse stock split completed in December 2025, ensuring compliance restoration efficiently, which not only boosts market confidence but also provides greater flexibility for future capital operations.
- CEO Statement: CEO Mark Reisenauer expressed satisfaction with the regained compliance, emphasizing that this achievement lays a foundation for the company's future growth and demonstrates Assertio's ongoing competitiveness in the pharmaceutical market.
- Company Background: Assertio is a pharmaceutical company focused on oncology, neurology, and pain management, dedicated to offering differentiated products designed to meet patient needs, and will continue to drive innovation to support patient health.
See More
Assertio Reports Positive Results for Same-Day Dosing of Rolvedon in Clinical Trial
- Clinical Trial Success: Assertio's Rolvedon demonstrated efficacy and safety comparable to next-day dosing in a clinical trial, indicating its potential for improving patient treatment experiences in early-stage breast cancer.
- Patient Participation: Conducted across 13 sites in the U.S., the study enrolled 53 patients, with 49 completing the trial, showcasing the feasibility of administering Rolvedon 30 minutes post-chemotherapy, thereby enhancing its clinical applicability.
- Low Adverse Event Rate: Only one patient experienced febrile neutropenia during the trial, with no hospitalizations or antibiotic treatments required, indicating good safety for same-day dosing, which could reduce healthcare costs.
- Future Development Potential: The study results provide crucial data supporting same-day dosing of Rolvedon, potentially leading to broader clinical applications and further solidifying Assertio's market position in oncology treatment.
See More
Assertio Reports Positive Clinical Trial Results for Rolvedon with Same-Day Dosing
- Clinical Trial Success: Assertio's Rolvedon demonstrated similar efficacy and safety in a clinical trial for early-stage breast cancer patients using a same-day dosing schedule, indicating a more convenient treatment option for patients.
- Efficacy Data: Among 53 participants, Rolvedon administered 30 minutes after TC chemotherapy showed a mean time to absolute neutrophil count (ANC) recovery of 1.8 days in Cycle 1, with only one patient experiencing febrile neutropenia, highlighting its strong safety profile.
- Study Impact: This study provides the oncology community with valuable insights into the potential utility of same-day GCSF therapy, which may enhance treatment experiences for early-stage breast cancer patients and reduce infection risks, thereby improving quality of life.
- Market Outlook: Rolvedon is considered a core growth asset for Assertio, and with the release of clinical data, it is expected to drive further penetration and sales growth in the oncology market.
See More
Assertio Holdings declares a 1-for-15 reverse stock split.
Reverse Stock Split Announcement: Assertio Holdings (ASRT) will execute a one-for-fifteen reverse split of its common stock, effective December 26, 2025, at 12:01 a.m. Eastern Time.
Trading Adjustments: The company's common stock will begin trading on a split-adjusted basis when the market opens on the same day, December 26, 2025.
See More
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.
KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.
Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.
Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Assertio Holdings Regains Nasdaq Compliance with Minimum Bid Price Rule
- Compliance Regained: Assertio Holdings announced that as of January 12, 2026, it has successfully regained compliance with Nasdaq listing requirements by maintaining a minimum bid price of $1.00 per share for ten consecutive days, marking a significant achievement in capital allocation flexibility.
- Successful Reverse Split: The company effectively increased its stock price through a reverse stock split completed in December 2025, ensuring compliance restoration efficiently, which not only boosts market confidence but also provides greater flexibility for future capital operations.
- CEO Statement: CEO Mark Reisenauer expressed satisfaction with the regained compliance, emphasizing that this achievement lays a foundation for the company's future growth and demonstrates Assertio's ongoing competitiveness in the pharmaceutical market.
- Company Background: Assertio is a pharmaceutical company focused on oncology, neurology, and pain management, dedicated to offering differentiated products designed to meet patient needs, and will continue to drive innovation to support patient health.
See More
Assertio Reports Positive Results for Same-Day Dosing of Rolvedon in Clinical Trial
- Clinical Trial Success: Assertio's Rolvedon demonstrated efficacy and safety comparable to next-day dosing in a clinical trial, indicating its potential for improving patient treatment experiences in early-stage breast cancer.
- Patient Participation: Conducted across 13 sites in the U.S., the study enrolled 53 patients, with 49 completing the trial, showcasing the feasibility of administering Rolvedon 30 minutes post-chemotherapy, thereby enhancing its clinical applicability.
- Low Adverse Event Rate: Only one patient experienced febrile neutropenia during the trial, with no hospitalizations or antibiotic treatments required, indicating good safety for same-day dosing, which could reduce healthcare costs.
- Future Development Potential: The study results provide crucial data supporting same-day dosing of Rolvedon, potentially leading to broader clinical applications and further solidifying Assertio's market position in oncology treatment.
See More
Assertio Reports Positive Clinical Trial Results for Rolvedon with Same-Day Dosing
- Clinical Trial Success: Assertio's Rolvedon demonstrated similar efficacy and safety in a clinical trial for early-stage breast cancer patients using a same-day dosing schedule, indicating a more convenient treatment option for patients.
- Efficacy Data: Among 53 participants, Rolvedon administered 30 minutes after TC chemotherapy showed a mean time to absolute neutrophil count (ANC) recovery of 1.8 days in Cycle 1, with only one patient experiencing febrile neutropenia, highlighting its strong safety profile.
- Study Impact: This study provides the oncology community with valuable insights into the potential utility of same-day GCSF therapy, which may enhance treatment experiences for early-stage breast cancer patients and reduce infection risks, thereby improving quality of life.
- Market Outlook: Rolvedon is considered a core growth asset for Assertio, and with the release of clinical data, it is expected to drive further penetration and sales growth in the oncology market.
See More
Assertio Holdings declares a 1-for-15 reverse stock split.
Reverse Stock Split Announcement: Assertio Holdings (ASRT) will execute a one-for-fifteen reverse split of its common stock, effective December 26, 2025, at 12:01 a.m. Eastern Time.
Trading Adjustments: The company's common stock will begin trading on a split-adjusted basis when the market opens on the same day, December 26, 2025.
See More
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.
KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.
Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.
Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.
See More
